Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
April 08 2013 - 1:00PM
Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage
biopharmaceutical company focused on the development of oncology
therapeutics, today announced the presentation of data examining
onapristone's effect on preclinical models of breast cancer,
utilizing a biomarker, which has the potential to identify patients
with certain cancers that may best respond to onapristone therapy.
The findings were reported in a poster entitled "Antiprogestin drug
development: In vitro validation of a potential clinical
biomarker," presented today at the American Association for Cancer
Research (AACR) Annual Meeting 2013 in Washington, DC.
Onapristone is Arno's investigational progestin receptor
antagonist that has demonstrated anti-tumor activity in preclinical
and clinical studies of hormone-dependent tumors. In this
preclinical study, onapristone showed inhibitory effects in cell
lines with activated progesterone receptors (APR). Along with
data previously presented at the 2012 San Antonio Breast Cancer
Symposium, researchers concluded that the immunohistochemistry
(IHC) technique developed to identify activated progesterone
receptors in tumors may be applicable in the clinical
setting.
"We are continuing to move forward with our plans to develop a
companion diagnostic to test patients' tumor samples for APR," said
Alexander Zukiwski, Vice President and Chief Medical Officer of
Arno, and an author of the study. "Identifying this biomarker
brings us one step closer to initiating Phase II clinical trials
for onapristone. The results seen thus far indicate that
tumors expressing APR may best respond to
onapristone. Additionally, as we move forward with planned
studies in breast and endometrial cancer, we are continuing to test
other cancer samples that may also express APR. "
In the study, researchers examined six human breast cancer and
two human endometrial cancer cell lines. Using the novel IHC
technique, as well as Western Blotting, investigators determined
whether each cell line was positive or negative for activated
progesterone receptors. When exposed to onapristone, the cell
lines that were positive for APR responded to the treatment while
the cells lines not exhibiting APR did not.
Arno Therapeutics plans to initiate Phase I clinical studies in
onapristone in the second half of 2013.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company
developing innovative products for the treatment of cancer.
Arno has exclusive worldwide rights to develop and market three
innovative anti-cancer product candidates. These compounds
are in clinical or preclinical development as potential best- or
first-in-class products to treat hematologic malignancies and solid
tumors. For more information about the company, please
visit www.arnothera.com.
Forward-Looking Statements: This press
release contains forward-looking statements that involve
substantial risks and uncertainties. These statements are often,
but not always, made through the use of words or phrases such as
"anticipates," "expects," "plans," "believes," "intends," and
similar words or phrases. These forward-looking statements include,
without limitation, statements regarding the timing, progress and
anticipated results of the clinical development of onapristone, and
Arno's strategy, future operations, outlook, milestones, future
financial position, future financial results, plans and objectives.
We may not actually achieve these plans, intentions or expectations
and Arno cautions investors not to place undue reliance on our
forward-looking statements. Actual results or events could differ
materially from the plans, intentions and expectations disclosed in
the forward-looking statements we make. Various important factors
could cause actual results or events to differ materially from the
forward-looking statements that we make. Such factors include,
among others, risks that the results of clinical trials will not
support our claims or beliefs concerning the effectiveness of
onapristone or any of our other product candidates, our ability to
finance the development of our product candidates, regulatory
risks, and our reliance on third party researchers and other
collaborators. Additional risks are described in the company's
Annual Report on Form 10-K for the year ended December 31,
2012. Arno is providing this information as of the date of this
press release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future
events or otherwise.
CONTACT: The Ruth Group
Stephanie Carrington (investors)
scarrington@theruthgroup.com
(646) 536-7017
Arno Therapeutics
Glenn Mattes
gm@arnothera.com
862-703-7176
Caitlin Cox (media)
ccox@theruthgroup.com
(646) 536-7033
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jul 2023 to Jul 2024